A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.
about
Vaccine protection against Zika virus from BrazilLong-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai ChildrenDengue Fever: Causes, Complications, and Vaccine StrategiesLatest developments and future directions in dengue vaccinesVaccines and immunization strategies for dengue preventionCurrent progress in dengue vaccinesThe role of the mosquito in a dengue human infection modelInduction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States.Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentDengue vaccines: recent developments, ongoing challenges and current candidates.Rapid development of a DNA vaccine for Zika virusDengue vaccines: strongly sought but not a reality just yetIdentification of conserved and HLA promiscuous DENV3 T-cell epitopes.An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.Dengue vaccine: come let's fight the menace.A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 studyPolytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies.Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.Central nervous system infections in travelers.Developing a dengue vaccine: progress and future challenges.Recent progress in dengue vaccine development.Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?Working towards dengue as a vaccine-preventable disease: challenges and opportunities.Dengue Virus Exposures Among Deployed U.S. Military Personnel.A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate.Dengue infection.Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.Live viral vaccines in immunocompromised patientsRecent Developments in Recombinant Protein-Based Dengue Vaccines
P2860
Q25165129-06962C22-8595-4492-BAEB-147C36AE5937Q26314710-68BC6EAA-7CEC-4C95-AF8E-5177C8237A09Q26700082-490C3759-FA6D-4715-A18F-65B6D6C41AECQ27023422-43CA0627-B349-4612-90CA-4A86D14DF234Q28077521-E98D29D2-0717-4E3C-B4EB-C27302005B71Q33408300-6447F0E5-892F-44D4-9E41-B08D985F011BQ33676847-4269C8B0-8788-4CA8-971B-9A609C8B9EE3Q33699057-D8AB7CFE-E80D-47F7-9521-ED96C0701F63Q33743890-A98E6194-A14E-495E-98D9-6622224E25EFQ33773563-39EAC3CA-DE69-4738-831D-C33FBCD80229Q33841045-3D63719C-BAEE-412A-84CB-D40A41311613Q34238916-319348E0-A228-4F19-BA3B-E4BE981F1BEDQ34367194-D833EC61-4D46-4DD0-9C01-D064FB9F512DQ34542032-F9502A12-A83C-4C53-9AA5-8C190C3DF50BQ35008771-C60042C6-E870-4F61-B3A3-B7935B81EE21Q35018972-7278E023-E018-46EF-86FF-E035A55E98CDQ35272502-79E7BAA4-E31C-4251-A4DA-055FB1A7EF94Q35781300-442D49B8-4F35-40AF-A55F-47FD96B04A43Q35887206-4C9FA536-E6DD-44FB-B59C-7A15FBF70EFFQ36026204-4817BF8A-C070-45E1-A9CA-127E259717CEQ36026210-13819E72-C59A-475C-A3E9-C88E63A8E5C4Q36288109-B215F6D0-6521-41F9-8C2D-97C1244CCC3CQ37723038-214522B6-219D-4BF0-A601-2F56DE393E13Q38157106-B8B50A25-B010-46CF-B080-471B9D9C7B61Q38159976-1849CE54-F13F-4111-A7BE-77D68B9D1E54Q38201151-E32996A1-F220-49AC-861A-A0AC34032EE3Q38303232-A347487E-3A3E-4724-97ED-C8019FB3DD69Q38618056-2DF3DE6A-0438-42B7-85D9-F810679F3794Q38657783-E293ACB2-5517-43BD-BD1F-B5E97AC97C3CQ38963303-53CE665B-A787-46D3-BDB1-260EBF95E3BEQ42977175-AFFC908F-47DE-41AD-9FF8-F9FF0281ECBDQ42996339-A4A6E70A-FFA1-4A98-BA64-C872260F1EDCQ47202176-59801FD9-2C2A-4ACB-A747-1B080DA7C0D0Q52662743-A064E56E-E6D8-4A07-8F17-3342FBEFABDFQ54260853-D460F395-6B3B-4413-96EB-CFD061B026E6Q55387941-7A87BB36-40FC-4DE6-993C-6C9E1A7EDA51Q56765765-D185B3C0-CC9B-4A82-8C15-A12CCA834C9EQ56960671-E1E7719C-41AC-49DE-8637-C514B291C2AE
P2860
A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@ast
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@en
type
label
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@ast
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@en
prefLabel
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@ast
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@en
P2093
P2860
P1476
A phase II, randomized, safety ...... rus vaccine in healthy adults.
@en
P2093
Francis Dessy
Isabelle Carletti
Kenneth H Eckels
Kristen Bauer
Rafael De La Barrera
Robert Putnak
Robert V Gibbons
Stefan Fernandez
Stephen J Thomas
Wellington Sun
P2860
P356
10.4269/AJTMH.2012.12-0361
P407
P577
2012-12-03T00:00:00Z